Abstract P4-12-23: Z-Endoxifen-PROTAC, a novel drug for chemo-sensitive and-resistant Triple Negative Breast Cancer
Swaathi Jayaraman(Johns Hopkins University), Matthew P. Goetz(Mayo Clinic), Sayantani Sarkar Bhattacharya(Indian Institute of Chemical Biology), Akhilesh Pandey(Mayo Clinic), Stephanie L. Safgren(Mayo Clinic), Joel M. Reid(Children's Hospital of Philadelphia), John R. Hawse(Mayo Clinic in Arizona), Thomas R. Caulfield(Jacksonville College), Matthew M. Ames(Mayo Clinic), James N. Ingle(Mayo Clinic), Mary J. Kuffel(Mayo Clinic in Arizona), Matthew J. Schellenberg(Mayo Clinic), Jasmine K. Farmakes, Sarah A. Buhrow(Mayo Clinic)
Cited by 1
Related Papers
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k